BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32978904)

  • 21. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma.
    Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32579175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
    Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
    Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process.
    Kong W; Gao M; Jin Y; Huang W; Huang Z; Xie Z
    Aging (Albany NY); 2020 Aug; 12(16):16555-16578. PubMed ID: 32852285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
    Wang Y; Liu T; Zhang K; Huang RH; Jiang L
    Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy.
    Fu Q; Yang F; Xiang T; Huai G; Yang X; Wei L; Yang H; Deng S
    Sci Rep; 2018 May; 8(1):7933. PubMed ID: 29785036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma.
    Chang Q; Xu Y; Wang J; Jing H; Rao L; Tang W; Zhang Z; Wu X
    Comput Math Methods Med; 2021; 2021():8556888. PubMed ID: 34819993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
    Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
    Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
    Wang L; Wang Q; Li Y; Qi X; Fan X
    J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Xu H; Xiong C; Chen Y; Zhang C; Bai D
    Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of 40S ribosomal protein S8 as a novel biomarker for alcohol‑associated hepatocellular carcinoma using weighted gene co‑expression network analysis.
    Bi N; Sun Y; Lei S; Zeng Z; Zhang Y; Sun C; Yu C
    Oncol Rep; 2020 Aug; 44(2):611-627. PubMed ID: 32627011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HN1 as a diagnostic and prognostic biomarker for liver cancer.
    Liu Z; Yang D; Li Y; Jiao Y; Lv G
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32700728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
    Guan Z; Cheng W; Huang D; Wei A
    Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.